3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
6
Recruiting
4
Not yet recruiting
2
Withdrawn
1
Terminated
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasm Metastasis
4
Carcinoma, Non-Small-Cell Lung
4
Neoplasms
2
Melanoma
2
Lung Neoplasms
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Radiation Pneumonitis
1
Pleural Mesothelial Neoplasm
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Oropharyngeal Neoplasms
1
Neoplasms, Glandular and Epithelial
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasm, Residual
1
Mouth Neoplasms
1
Liver Neoplasms
1
Liver Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Esophageal Neoplasms
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Interventions
durvalumab
18
Bevacizumab
17
atezolizumab
13
lenvatinib
10
Magnetic Resonance Spectroscopy
10
tremelimumab
8
Nivolumab
8
pembrolizumab
7
Sorafenib
6
Specimen Handling
5
camrelizumab
4
cabozantinib
4
Immunoglobulin G
4
Disulfides
4
sintilimab
3
apatinib
3
X-Rays
3
Radiotherapy
3
Radiofrequency Ablation
3
Radiation
3
Hepatectomy
3
E-7386
3
Doxorubicin
3
Cyclophosphamide
3
tislelizumab
2
relatlimab
2
dostarlimab
2
budigalimab
2
Standard of Care
2
Simvastatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Carcinoma, Hepatocellular
×
Immunotherapy
×
Clear all
NCT05063565
2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2
Active not recruiting
100 enrolled